Internal Medicine, Nephrology · Los Angeles, CA
NPI
1811008022
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
6333 Wilshire Blvd, Suite 200
Los Angeles, CA, 90048
Phone (323) 653-2504
Groups this clinician bills Medicare through
Medicare paid, 2024
$346K
4,721 services
Medicare patients, 2024
572
Average age 81
Drug cost, 2024
$4.2M
21,046 prescriptions
Company payments, 2025
$3,406
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ilya Gelman was code 99214 (office e&m - established), 1,469 times for 454 patients. In total Ilya Gelman billed 4,721 services in 25 codes, and Medicare paid $346K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-12-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,469 | 454 | $108.51 | $159K |
| 36415 Venipuncture Blood Collection | Office | 974 | 404 | $8.65 | $8,425 |
| 99491 Chronic, Principal, and Transitional Care Management | Office | 716 | 197 | $71.55 | $51K |
| 99232 Hospital E&M - Subsequent | Facility | 534 | 83 | $64.89 | $35K |
| 99443 Telephone Services | Office | 217 | 140 | $103.57 | $22K |
| 99233 Hospital E&M - Subsequent | Facility | 201 | 65 | $97.60 | $20K |
| 99222 Hospital E&M - Initial | Facility | 139 | 89 | $107.25 | $15K |
| 99204 Office E&M - New | Office | 98 | 98 | $140.32 | $14K |
| 99215 Office E&M - Established | Office | 64 | 54 | $154.34 | $9,878 |
| 93000 Electrocardiogram | Office | 63 | 51 | $12.40 | $781 |
| G0008 Administration of influenza virus vaccine | Office | 60 | 60 | $35.02 | $2,101 |
| 90661 Vaccine Product | Office | 60 | 60 | $36.11 | $2,167 |
| G0179 Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 37 | 31 | $36.87 | $1,364 |
| G0181 Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 29 | 24 | $88.55 | $2,568 |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 22 | 22 | $46.44 | $1,022 |
By year: 2022 $280K for 3,728 services; 2023 $310K for 4,139 services; 2024 $346K for 4,721 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 974 | 404 | $8.65 | $8,425 |
Medicare prescription drug claims, 2024
In 2024, the drug Ilya Gelman prescribed most often to Medicare patients was Febuxostat, with 1,072 prescriptions and refills. In total Ilya Gelman wrote 21,046 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Febuxostat Generic | 1,072 | 1,112 | 116 | $86K |
| Rosuvastatin Calcium Generic | 882 | 1,075 | 105 | $3,871 |
| Dexlansoprazole Dr Dexlansoprazole | 638 | 662 | 68 | $116K |
| Furosemide Generic | 592 | 625 | 78 | $860 |
| Icosapent Ethyl Generic | 553 | 553 | 79 | $86K |
| Levothyroxine Sodium Generic | 549 | 646 | 66 | $1,873 |
| Mounjaro Tirzepatide | 518 | 524 | 67 | $537K |
| Vascepa Icosapent Ethyl | 511 | 533 | 64 | $182K |
| Ozempic Semaglutide | 455 | 466 | 61 | $430K |
| Hydralazine Hcl Generic | 420 | 427 | 57 | $1,939 |
| Dapagliflozin Dapagliflozin Propanediol | 409 | 412 | 47 | $204K |
| Amlodipine Besylate Generic | 382 | 425 | 49 | $612 |
| Nebivolol Hcl Generic | 364 | 402 | 41 | $19K |
| Jardiance Empagliflozin | 299 | 303 | 35 | $178K |
| Gabapentin Generic | 296 | 308 | 40 | $887 |
Brand drugs: 6,396 claims; generic drugs: 14,568 claims; opioid claims: 237.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ilya Gelman $3,406 ($3,406 in general payments such as food, travel and fees) from 30 companies. The largest payer was Abbvie Inc. with $555.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 16 | $555 |
| Novartis Pharmaceuticals Corporation NVS | 14 | $292 |
| Amgen Inc. AMGN | 15 | $283 |
| Radius Health, Inc. | 9 | $225 |
| ANI Pharmaceuticals, Inc. ANIP | 7 | $193 |
| Edwards Lifesciences Corporation EW | 4 | $183 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 7 | $183 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $160 |
| Novo Nordisk Inc NVO | 6 | $145 |
| Shield Therapeutics Inc STX.L | 5 | $124 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.